DOCSLIB.ORG

Final Program

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Final Program 17th World Congress on Ultrasound in Obstetrics and Gynecology 7–11 October 2007, Florence, Italy Final Program 19 crediti ECM italiana EACCME credits applied for Organised by The International Society of Ultrasound in Obstetrics and Gynecology www.isuog.org Venue floor plans Key: Sponsor activities Gynecology sessions entrance and PALAZZO DEGLI AFFARI registration Exhibition Poster rooms PDA Obstetrics sessions Meeting Rooms PALAZZO DEI CONGRESSI PDC LIMONAIA VENUE FLOOR PLANS / WELCOME MESSAGE Welcome message Dear colleagues, It is a pleasure and an honour for us to host for the first time ISUOG’s World Congress in Italy, in one of its most enchanting and beautiful cities, Florence. We are proud to announce that in this edition, as in those of the past few years, we have broken all records in terms of abstract submissions and subscriptions: we have received over 1000 abstracts and are expecting more than 1700 delegates from all over the world. On behalf of ISUOG, we thank all of you for your trust and enthusiasm and we assure you that we will do our best to make your stay in Florence unforgettable. There will be six pre-congress courses covering key aspects of our discipline, from fetal echocardiography and neurosonology to 3D, Doppler and gynaecologic ultrasound. The scientific program includes parallel sessions, debates and, based on the success of similar events in the past world congresses, some fun sessions such as role- plays and “Who wants to be an ultrasound millionaire”. The main sessions incorporate the ever popular live scan demonstrations of normal ultrasound findings by leading world experts, including new ‘tips and tricks’ for particular investigations. One parallel stream will be translated into Italian and will form the basis for Italian CME participation. We will also try to make the social program as pleasurable for you as the scientific one, with possibilities to make unforgettable excursions to splendid Tuscany sites, leaving at the same time the opportunity to profit from an escape to some of the most important outlets from world renowned Italian fashion designers as Prada or Gucci. The Congress party will be held in a romantic and beautiful 17th century aristocratic Palazzo on the Arno banks where Italian gourmet delicacies will be served. On behalf of our Scientific and Meeting Planning Committees, we are honoured to welcome you all here in Florence. Enrico Ferrazzi, Dario Paladini, Gianluigi Pilu Organising Committees CONTENTS ISUOG President Contents ● K. Hecher, Germany Congress Co-Chairmen, Italy Program (general) ● E. Ferrazzi ● D. Paladini ● G. Pilu Critical dates and times 2 Local Organising Committee, Italy ● D. Arduini Program orientation 2 ● F. Branconi ● M. Coccia Program at a glance 6 ● V. D’Addario ● T. Frusca Posters at a glance 8 ● U. Nicolini ● G. Monni Invited speaker declarations 9 ● N. Rizzo ● P. Scollo ● F. Severi CME accreditation 9 ● F. Taddei ● A. Testa Chairperson, speaker and poster presenter guidelines 10 ● T. Todros ● P. Volpe ISUOG Meeting Planning Program (in detail) Committee ● A. Tabor, Denmark (Chair) Pre-Congress courses – Sunday 7 October 2007 11 ● A. Abuhamad, USA ● T. Bourne UK Program – Monday 8 October 2007 16 ● J. Copel, USA ● A. Gagnon, Canada Posters – Monday 8 October 2007 23 ● K. Hecher, Germany ● K. Nicolaides UK ● D. Nyberg, USA Program – Tuesday 9 October 2007 33 ● G. Pilu, Italy ● L. Platt, USA Posters – Tuesday 9 October 2007 40 ● Y. Ville, France ISUOG Scientific Committee Program – Wednesday 10 October 2007 46 ● A. Baschat, USA (Chair) ● B. Benacerraf, USA Posters – Wednesday 10 October 2007 54 ● C. Bilardo, Netherlands ● T. Bourne, UK Program – Thursday 11 October 2007 61 ● E. Ferrazzi, Italy ● S. Goldstein, USA ● K. Mars˘ál, Sweden Posters – Thursday 11 October 2007 65 ● K. Nicolaides, UK ● A. Papageorghiou, UK ● B. Thilaganathan, UK Industry ● D. Timmerman, Belgium ● L. Valentin, Sweden Exhibition floor plan and list of exhibitors 4 ● Y. Ville, France ● S. Yagel, Israel Sponsors’ activities 70 Executive Director Exhibitor profiles 72 ● S. Johnson, UK ISUOG Secretariat Unit 4 Blythe Mews, Blythe Road, Social program 78 London W14 0HW, UK Tel: +44 (0) 20 7471 9955 Fax: +44 (0) 20 7471 9959 ISUOG business meetings 79 Email: [email protected] Website: www.isuog.org General information 79 1 Critical dates and times Registration opening hours The organisers cannot guarantee that PowerPoint posters can be included if they were not received in advance. Presenters should The registration area is at the entrance to the Congress building in attend the speaker preparation room to confirm their presentation Piazza Adua. is included. The opening times are: Sunday 7 October 2007 07:30–20:00 Scientific program hours Monday 8 October 2007 07:30–17:30 The scientific program sessions will take place in the PDC Tuesday 9 October 2007 08:00–17:30 Auditorium, the PDA Basement and the PDA Second Floor. Wednesday 10 October 2007 08:00–17:30 Please refer to the program for the exact location and timings of Thursday 11 October 2007 08:00–13:30 each session. Exhibition opening hours Sessions will take place during the following times: The exhibition will be located in the PDA and the PDC: Monday 8 October 2007 08:30–18:10 Monday 8 October 2007 09:30–17:00 Tuesday 9 October 2007 08:30–18:00 Tuesday 9 October 2007 09:30–17:00 Wednesday 10 October 2007 08:30–17:35 Wednesday 10 October 2007 09:30–17:00 Thursday 11 October 2007 08:30–13:30 Thursday 11 October 2007 09:30–13:00 PDC Poster sessions take place in the PDC (ground and first floor) and 09:30–12:00 PDA the PDA (first, second and third floors). Viewing is available from 09:00–17:00 Monday to Wednesday, and 09:00–13:30 on Speakers’ preparation room opening hours Thursday. Chaired poster discussions take place daily at 10:00. Speakers must check in their presentation at the speakers’ preparation room at least four hours prior to the commencement of ISUOG meetings the session in which they are to be presented (and ideally the day ISUOG Annual General Meeting (AGM) before) to ensure that their presentation is included. All fully paid delegates are enrolled as ISUOG members and CRITICALAND TIMES / PROGRAM ORIENTATION DATES The speakers’ preparation room will be located in room 9 on the invited to attend the AGM. ground floor of the PDC, opening hours are as follows: Sunday 7 October 2007 15:00–18:00 Tuesday 9 October at 15:30 Monday 8 October 2007 08:00–17:30 PDC Auditorium Tuesday 9 October 2007 08:00–17:30 For details of scheduled ISUOG Committee meetings, please refer Wednesday 10 October 2007 08:00–17:30 to page 79 of this brochure. Thursday 11 October 2007 08:00–13:00 Identification badges You will be given a name badge when you register which also contains all your essential tickets and access passes. Please make sure that you keep your badge safe and that you wear it at all times during the Congress. Due to the high number of delegates in attendance, we will have to turn anyone away from the session halls who is not wearing a valid badge. We ask you please to be understanding of this restriction as it is imposed for the safey and comfort of all attendees. Program orientation ● The program at a glance gives you an outline to each day’s events including locations, titles and times, and refreshment breaks. ● The program pages give you the detailed chronological listing of events – please note that all sessions run in parallel so you will need to read through all sessions of similar time to decide which best suits your needs. ● Buildings (PDC and PDA) as well as days are colour coded to assist you in ‘navigating’ the program. ● Rooms in each building are listed by building, floor and room. For example, PDC G.01 (Palazzo dei Congressi, ground floor, room 1); PDA 1.01 (Palazzo degli Affari, first floor, room 1). ● In all poster and oral presentation listings the presenting author name is underlined. ● All presentations which are supported by free communication abstracts have an OC (oral communication), OP (oral poster) or P (poster) number listed next to them: you can use this to refer to the Abstract book in your congress bag and the detailed abstract. ● Some of the sessions include ‘live scan’ time: these are live updates on the latest techniques and technologies in the field which support the scientific data in the same subject area. ● The poster titles are listed in the pages immediately following the day of oral sessions. Oral posters are referenced as ‘OP’ numbers and view only posters are referenced as ‘P’ numbers – you can use these both to locate the original abstracts and to find the relevant posters in the dedicated poster areas. ● There are allocated chaired poster discussion times for oral poster sessions (OP) at 10:00 daily. ● The exhibition opens at 09:30 each day in time for the morning coffee break. All refreshment breaks are located within the exhibition areas. ● All oral poster (chaired discussion) sessions will be judged within their subject categories. The best oral poster presenters in each session will receive certificates and will be formally acknowledged in the Ultrasound in Obstetrics & Gynecology Journal. 2 VENUE FLOOR PLANS Venue floor plans Key: Sponsor activities Gynecology sessions entrance and PALAZZO DEGLI AFFARI Exhibition Poster rooms registration PDA Obstetrics sessions Meeting Rooms PALAZZO DEI CONGRESSI PDC LIMONAIA PDC 2 PDA 3 PDA 2 PDC 1 PDA 1 PDC G 3 Exhibitor listing and floor plans Lower levels Palazzo dei Congressi EXHIBITOR LISTING AND FLOOR PLANS LISTING EXHIBITOR Exhibitor listing: lettered stands A Congrex AB B International Vasa Previa Foundation Inc.
Load more

Recommended publications
  • The Fetal Center SPRING 2019 JOURNAL in This Issue
    The Fetal Center SPRING 2019 JOURNAL In This Issue FEATURES: TAKING THE RESEARCH LONG VIEW TOWARD PREVENTION OF RHESUS DISEASE 06 A New Clinical Trial: Umbilical Cord Blood Mononuclear Cells for Hypoxic Neurologic Injury 01 Leaders in Innovation: Rhesus Disease in Infants with Congenital Diaphragmatic Hernia Diagnosis and Treatment NEWS OF NOTE 04 A Miracle Baby for the Pinedas 08 The Fetal Center Welcomes New Recruits 09 NAFTNet Leadership Contact Us THE FETAL CENTER AT CHILDREN’S MEMORIAL HERMANN HOSPITAL UT Physicians Professional Building 6410 Fannin, Suite 210 Houston, TX 77030 Phone: 832.325.7288 Fax: 713.383.1464 Email: [email protected] Located within the Texas Medical Center, The Fetal Center is affiliated with Children’s ★FETAL Memorial Hermann Hospital, McGovern Medical NR School at UTHealth, and UT Physicians. To view The Fetal Center’s online resources, visit childrens.memorialhermann.org/thefetalcenter. FEATURE Leaders in Innovation: Rhesus Disease Diagnosis and Treatment Rhesus (Rh) disease, also known as Reproductive Sciences and the department of Rh-induced hemolytic disease of the Pediatric Surgery at McGovern Medical School at UTHealth. “The antibodies don’t usually cause fetus and newborn (HDFN), rhesus problems during a first pregnancy, because the baby alloimmunization or erythroblastosis may be born before the level of antibodies is high enough to have an effect. Rh antibodies are more fetalis, is relatively rare, occurring in likely to cause problems in second or later pregnan- about 2.5 out of every 100,000 live cies if the baby is Rh positive. Rh antibodies cross the placenta and attack the baby’s red blood cells, births in countries with well-established causing hemolytic anemia in the baby and leading to healthcare infrastructures.
    [Show full text]
  • Hemolytic Disease of the Newborn
    Intensive Care Nursery House Staff Manual Hemolytic Disease of the Newborn INTRODUCTION and DEFINITION: Hemolytic Disease of the Newborn (HDN), also known as erythroblastosis fetalis, isoimmunization, or blood group incompatibility, occurs when fetal red blood cells (RBCs), which possess an antigen that the mother lacks, cross the placenta into the maternal circulation, where they stimulate antibody production. The antibodies return to the fetal circulation and result in RBC destruction. DIFFERENTIAL DIAGNOSIS of hemolytic anemia in a newborn infant: -Isoimmunization -RBC enzyme disorders (e.g., G6PD, pyruvate kinase deficiency) -Hemoglobin synthesis disorders (e.g., alpha-thalassemias) -RBC membrane abnormalities (e.g., hereditary spherocytosis, elliptocytosis) -Hemangiomas (Kasabach Merritt syndrome) -Acquired conditions, such as sepsis, infections with TORCH or Parvovirus B19 (anemia due to RBC aplasia) and hemolysis secondary to drugs. ISOIMMUNIZATION A. Rh disease (Rh = Rhesus factor) (1) Genetics: Rh positive (+) denotes presence of D antigen. The number of antigenic sites on RBCs varies with genotype. Prevalence of genotype varies with the population. Rh negative (d/d) individuals comprise 15% of Caucasians, 5.5% of African Americans, and <1% of Asians. A sensitized Rh negative mother produces anti-Rh IgG antibodies that cross the placenta. Risk factors for antibody production include 2nd (or later) pregnancies*, maternal toxemia, paternal zygosity (D/D rather than D/d), feto-maternal compatibility in ABO system and antigen load. (2) Clinical presentation of HDN varies from mild jaundice and anemia to hydrops fetalis (with ascites, pleural and pericardial effusions). Because the placenta clears bilirubin, the chief risk to the fetus is anemia. Extramedullary hematopoiesis (due to anemia) results in hepatosplenomegaly.
    [Show full text]
  • Role of Infection and Immunity in Bovine Perinatal Mortality: Part 2
    animals Review Role of Infection and Immunity in Bovine Perinatal Mortality: Part 2. Fetomaternal Response to Infection and Novel Diagnostic Perspectives Paulina Jawor 1,* , John F. Mee 2 and Tadeusz Stefaniak 1 1 Department of Immunology, Pathophysiology and Veterinary Preventive Medicine, Wrocław University of Environmental and Life Sciences, 50-375 Wrocław, Poland; [email protected] 2 Animal and Bioscience Research Department, Teagasc, Moorepark Research Centre, P61 P302 Fermoy, County Cork, Ireland; [email protected] * Correspondence: [email protected] Simple Summary: Bovine perinatal mortality (death of the fetus or calf before, during, or within 48 h of calving at full term (≥260 days) may be caused by noninfectious and infectious causes. Although infectious causes of fetal mortality are diagnosed less frequently, infection in utero may also compromise the development of the fetus without causing death. This review presents fetomaternal responses to infection and the changes which can be observed in such cases. Response to infection, especially the concentration of immunoglobulins and some acute-phase proteins, may be used for diagnostic purposes. Some changes in internal organs may also be used as an indicator of infection in utero. However, in all cases (except pathogen-specific antibody response) non-pathogen-specific responses do not aid in pathogen-specific diagnosis of the cause of calf death. But, nonspecific markers of in utero infection may allow us to assign the cause of fetal mortality to infection and thus Citation: Jawor, P.; Mee, J.F.; increase our overall diagnosis rate, particularly in cases of the “unexplained stillbirth”. Stefaniak, T. Role of Infection and Immunity in Bovine Perinatal Abstract: Bovine perinatal mortality due to infection may result either from the direct effects of Mortality: Part 2.
    [Show full text]
  • The Rhesus Factor and Disease Prevention
    THE RHESUS FACTOR AND DISEASE PREVENTION The transcript of a Witness Seminar held by the Wellcome Trust Centre for the History of Medicine at UCL, London, on 3 June 2003 Edited by D T Zallen, D A Christie and E M Tansey Volume 22 2004 ©The Trustee of the Wellcome Trust, London, 2004 First published by the Wellcome Trust Centre for the History of Medicine at UCL, 2004 The Wellcome Trust Centre for the History of Medicine at University College London is funded by the Wellcome Trust, which is a registered charity, no. 210183. ISBN 978 0 85484 099 1 Histmed logo images courtesy Wellcome Library, London. Design and production: Julie Wood at Shift Key Design 020 7241 3704 All volumes are freely available online at: www.history.qmul.ac.uk/research/modbiomed/wellcome_witnesses/ Please cite as : Zallen D T, Christie D A, Tansey E M. (eds) (2004) The Rhesus Factor and Disease Prevention. Wellcome Witnesses to Twentieth Century Medicine, vol. 22. London: Wellcome Trust Centre for the History of Medicine at UCL. CONTENTS Illustrations and credits v Witness Seminars: Meetings and publications;Acknowledgements vii E M Tansey and D A Christie Introduction Doris T Zallen xix Transcript Edited by D T Zallen, D A Christie and E M Tansey 1 References 61 Biographical notes 75 Glossary 85 Index 89 Key to cover photographs ILLUSTRATIONS AND CREDITS Figure 1 John Walker-Smith performs an exchange transfusion on a newborn with haemolytic disease. Photograph provided by Professor John Walker-Smith. Reproduced with permission of Memoir Club. 13 Figure 2 Radiograph taken on day after amniocentesis for bilirubin assessment and followed by contrast (1975).
    [Show full text]
  • Severe Fetomaternal Alloimmune Thrombocytopenia Presenting with Fetal Hydrocephalus
    PRENATAL DIAGNOSIS, VOL. 16 1 152-1 155 (1996) SHORT COMMUNICATION SEVERE FETOMATERNAL ALLOIMMUNE THROMBOCYTOPENIA PRESENTING WITH FETAL HYDROCEPHALUS M. F. MURPHY*, H. HAMBLEYt, K. NICOLAIDESS AND A. H. WATERS* *Department of Haematology, St Bartholomew's Hospital and tDepartment of Haematology and $Harris Birthright Fetal Medicine Research Centre, King's College Hospital, London, U K. Received 22 February 1996 Accepted 7 July 1996 SUMMARY We report two patients where the finding of isolated fetal hydrocephalus led to the detection of severe fetal thrombocytopenia, using fetal blood sampling. Serological investigation led to the diagnosis of fetomaternal alloimmune thrombocytopenia (FMAIT) due to anti-HPA- I a. Both women had had previous unsuccessful pregnancies probably due to FMAIT; one had had four miscarriages at 17-18 weeks' gestation. The other had had one previous pregnancy complicated by severe fetal anaemia, and eventually hydrocephalus developed and the fetus died without the diagnosis of FMAIT being considered. Subsequent pregnancies in the two women were also affected by FMAIT, but prenatal treatment, predominantly with serial fetal platelet transfusions, resulted in a successful outcome in both cases. These observations suggest that FMAIT should be suspected if there is isolated fetal hydrocephalus, unexplained fetal anaemia, or recurrent miscarriages. The accurate diagnosis of FMAIT is important because recent advances in prenatal management can improve the outcome of subsequently affected pregnancies. KEY WORDS: neonatal alloimmune thrombocytopenia; intrauterine haemorrhage; hydrocephalus INTRODUCTION (Mueller-Eckhardt et al., 1989; Kaplan et al., Fetomaternal incompatibility for human platelet 1991). In these studies, 1&15 per cent of infants antigens (HPAs) may cause maternal alloimmuni- had no bleeding manifestations but the remainder zation and fetal and neonatal thrombocytopenia had purpura, bruising, andor more severe haem- (Kaplan et al., 1991; Waters et al., 1991; Goldman orrhage.
    [Show full text]
  • Haematological Abnormalities in Mitochondrial Disorders
    Singapore Med J 2015; 56(7): 412-419 Original Article doi: 10.11622/smedj.2015112 Haematological abnormalities in mitochondrial disorders Josef Finsterer1, MD, PhD, Marlies Frank2, MD INTRODUCTION This study aimed to assess the kind of haematological abnormalities that are present in patients with mitochondrial disorders (MIDs) and the frequency of their occurrence. METHODS The blood cell counts of a cohort of patients with syndromic and non-syndromic MIDs were retrospectively reviewed. MIDs were classified as ‘definite’, ‘probable’ or ‘possible’ according to clinical presentation, instrumental findings, immunohistological findings on muscle biopsy, biochemical abnormalities of the respiratory chain and/or the results of genetic studies. Patients who had medical conditions other than MID that account for the haematological abnormalities were excluded. RESULTS A total of 46 patients (‘definite’ = 5; ‘probable’ = 9; ‘possible’ = 32) had haematological abnormalities attributable to MIDs. The most frequent haematological abnormality in patients with MIDs was anaemia. 27 patients had anaemia as their sole haematological problem. Anaemia was associated with thrombopenia (n = 4), thrombocytosis (n = 2), leucopenia (n = 2), and eosinophilia (n = 1). Anaemia was hypochromic and normocytic in 27 patients, hypochromic and microcytic in six patients, hyperchromic and macrocytic in two patients, and normochromic and microcytic in one patient. Among the 46 patients with a mitochondrial haematological abnormality, 78.3% had anaemia, 13.0% had thrombopenia, 8.7% had leucopenia and 8.7% had eosinophilia, alone or in combination with other haematological abnormalities. CONCLUSION MID should be considered if a patient’s abnormal blood cell counts (particularly those associated with anaemia, thrombopenia, leucopenia or eosinophilia) cannot be explained by established causes.
    [Show full text]
  • Hemolytic Disease of the Newborn
    & Throm gy b o o l e o t m Journal of Hematology & a b o m l e i c H D f Nandyal, J Hematol Thrombo Dis 2015, 3:2 o i s l e a Thromboembolic Diseases ISSN: 2329-8790 a n s r DOI: 10.4172/2329-8790.1000203 e u s o J Mini Review Open Access Hemolytic Disease of the Newborn Raja R Nandyal* Department of Hematology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA *Corresponding author: Raja R Nandyal, Department of Hematology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA, Tel: 0114055351615; E-mail: [email protected] Rec date: Mar 13, 2015, Acc date: Apr 14, 2015, Pub date: Apr 20, 2015 Copyright: © 2015 Nandyal RR. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited. Abstract Hemolytic disease of the newborn (HDN), with high potential for increased fetal loss is less common now, due to the universal screening for iso-sensitization and also because of appropriate use of antenatal anti-RhD antibody prophylaxis. There are other non-RhD antibodies that can cause HDN. In US, we occasionally encounter a highly sensitized fetus with significant morbidity and mortality. In utero RBC transfusions and Intravenous Immunoglobulin (IVIG) therapy for such an infant are effective to some extent, in the management of HDN. Partial exchange transfusions (immediately after the delivery) and double volume exchange transfusions are rarely but still, needed as rescue modes.
    [Show full text]
  • Rhesus Haemolytic Disease Is Entirely Preventable – but Many Babies Still Die (Or Suffer Disabilities) Because of It! DO NOT LET THIS HAPPEN!
    Rhesus Haemolytic Disease is entirely preventable – BUT many babies still die (or suffer disabilities) because of it! DO NOT LET THIS HAPPEN! FACT: Rhesus Haemolytic Disease is a condition caused by the incompatibility between the blood of the mother and that of her fetus. If the mother is Rh-negative and the fetus is Rh-positive, when the baby is born some of the fetus’ Rh-positive red blood cells may enter the mother’s blood stream. When this happens they sensitise the Rh(D)-negative mother and in subsequent Rh(D)-positive pregnancies, this may evoke a secondary immunological response with a rapid and important production of antibodies against the D antigen. Rh incompatibility usually does not cause problems during the first pregnancy, since the baby is born before antibodies develop. The condition is, therefore, more likely to cause problems in the second and subsequent pregnancies. RISK: When it occurs there is a substantial risk to the fetus THE CURRENT BURDEN OF RH DISEASE TODAY of still birth or disabilities, including kerniterus (which causes deafness or cerebral palsy), fetal hydrops, fetal anemia and jaundice. Current burden of disease: • 50,000 stillbirths 50 years ago the solution was found –and yet today it • 114,000 neonatal deaths is still common because approximatelyhalf of all at- • 40,000 kernicterus and risk women around the world still do not receive basic cerebral palsy • 60,000 kernicterus and protective therapy often because the required infusion is hearing loss not available or simply because the need to provide this essential protection has been forgotten! PREVENTION: Prevention of this condition can be reliably provided by providing an intramuscular injection of anti-D immunoglobulin immediately after delivery – and also as a prophylactic during 28 – 32 week period of pregnancy.
    [Show full text]
  • Correlation Between the Rhd Genotyping and Rhd Serotyping in Isoimmunized Pregnancies
    The Egyptian Journal of Medical Human Genetics (2011) 12, 127–133 Ain Shams University The Egyptian Journal of Medical Human Genetics www.ejmhg.eg.net www.sciencedirect.com ORIGINAL ARTICLE Correlation between the RhD genotyping and RhD serotyping in isoimmunized pregnancies Sahar M. Nour El Din a,*, Ahmed R.M. ARamy b, Mohamed S. Ali b a Medical Genetics Center, Ain-Shams University, Cairo, Egypt b Gynecological and Obstetric Department, Faculty of medicine, Ain Shams University, Cairo, Egypt Received 2 January 2011; accepted 3 April 2011 Available online 5 July 2011 KEYWORDS Abstract Alloimmunisation was one of the most important causes of perinatal mortality and mor- Maternal alloimmunization; bidity by the middle of the last century. The objective of the present study was to investigate the Rhesus; presence of the RHD gene in fetal cells (amniocytes) obtained from amniotic fluid by genotyping RHD; to compare it with the RhD serotyping. Also to correlate the presence of RhD gene with the neo- Isoimmunization; natal outcome. This work was carried out at Maternity hospital and Medical Genetics center, while Hydrops fetalis; PCR testing was done at the Medical Research center, Faculty of Medicine, Ain Shams University Fetus; in the period from 2008 to 2010. The present study included recruiting of 20 RhD negative (sensi- Rh negative tized to the RhD antigen) pregnant mothers. The entire study group was subjected to complete general, obstetric and a detailed obstetric ultrasonographic examination. Rh typing and indirect Coomb’s test were also done. Amniocentesis was performed with a 20-gauge needle under contin- uous ultrasound guidance.
    [Show full text]
  • Review of Fetal and Neonatal Immune Cytopenias
    Review of Fetal and Neonatal Immune Cytopenias Sharon Lewin, MD, and James B. Bussel, MD The authors are affiliated with Weill Cornell Abstract: The fetoplacental interface plays a unique role in pathol- Medical Center/New York Presbyterian ogies of the fetus and neonate, and is increasingly being recog- Hospital in New York, New York. Dr Lewin nized for effects on fetal and neonatal development that resonate is a clinical fellow in neonatology in the into adulthood. In this review, we will use several exemplary Division of Newborn Medicine in the Department of Pediatrics, and Dr Bussel is disorders involving each of the 3 types of blood cells to explore a professor of pediatrics and pediatrics in the effect of perinatal insults on subsequent development of the the Department of Obstetrics and Gynecol- affected cell line. We will present new data regarding outcomes ogy and in the Department of Medicine; he of infants treated prenatally for fetal and neonatal alloimmune is also the director of the Platelet Research thrombocytopenia (FNAIT) and contrast these with outcomes of and Treatment Program in the Division of infants affected by hemolytic disease of the fetus and newborn. Pediatric Hematology and Oncology in the Department of Pediatrics. We also will explore the differences between FNAIT and passively transferred antibodies, as seen in maternal idiopathic thrombo- Address correspondence to: cytopenic purpura. Neonatal hemochromatosis is an example James B. Bussel, MD of a disease that previously was largely fatal, but whose newly Professor of Pediatrics discovered etiology as an immune-mediated perinatal disorder Director has resulted in development of highly effective treatment.
    [Show full text]
  • Intravenous Immune Globulin Uses in the Fetus and Neonate: a Review
    antibodies Review Intravenous Immune Globulin Uses in the Fetus and Neonate: A Review Mahdi Alsaleem 1,2 1 Pediatrics Department, Neonatology, Children’s Mercy Hospital, Kansas City, MO 64108, USA; [email protected] 2 Pediatrics Department, University of Kansas, Wichita, KS 67208, USA Received: 31 August 2020; Accepted: 2 November 2020; Published: 4 November 2020 Abstract: Intravenous immune globulin (IVIG) is made after processing plasma from healthy donors. It is composed mainly of pooled immunoglobulin and has clinical evidence-based applications in adult and pediatric populations. Recently, several clinical applications have been proposed for managing conditions in the neonatal population, such as hemolytic disease of the newborn, treatment, and prophylaxis for sepsis in high-risk neonates, enterovirus parvovirus and COVID-19 related neonatal infections, fetal and neonatal immune-induced thrombocytopenia, neonatal hemochromatosis, neonatal Kawasaki disease, and some types of immunodeficiency. The dosing, mechanism of action, effectiveness, side effects, and adverse reactions of IVIG have been relatively well studied in adults but are not well described in the neonatal population. This review aims to provide the most recent evidence and consensus guidelines about the use of IVIG in the fetus and neonate. Keywords: immunoglobulins; fetus; neonates; sepsis; hemolysis; hyperbilirubinemia; necrotizing enterocolitis; coronavirus; coronavirus disease 19 (COVID-19) 1. Introduction Immunoglobulin therapy is defined as the use of a combination of antibodies obtained from healthy human donors to treat different conditions [1,2]. The principal components of intravenous immunoglobulin (IVIG) are IgG antibodies, which compromise about 90% of the IVIG. Antibodies are glycoproteins synthesized and secreted by plasma cells (activated B cells) to respond to antigenic stimulation with the primary purpose of a specific immune response to result in different physiological and/or pathological processes [2,3].
    [Show full text]
  • Immunohematology JOURNAL of BLOOD GROUP SEROLOGY and EDUCATION
    Immunohematology JOURNAL OF BLOOD GROUP SEROLOGY AND EDUCATION VOLUME 17, NUMBER 1, 2001 From the publishers of Immunohematology A Comprehensive Laboratory Manual Immunohematology Methods and Procedures Featuring— • Over 100 methods— just about every method used in a reference lab. • Eleven chapters discussing problems faced by blood group serologists and the procedures and methods that can be used to solve them. • An extra set of the methods to use at the bench, printed on durable waterproof paper. • See business reply order card enclosed in this issue or order on the Web at redcross.org/immunohematology Now available from Montgomery Scientific Publications APPLIED BLOOD GROUP SEROLOGY, 4th EDITION by Peter D. Issitt and David J. Anstee A totally revised, mostly rewritten, fully up-to-date edition of one of the most popular books about the blood groups and blood transfusion ever published. I 46 chapters, an increase of 16 over the third edition 1 ″× ″ • 1,208 plus xxiv 8 /2 11 pages, hardbound, fully indexed, over 1,500 entries I 260 tables and 112 figures, an increase of more than 60% over the third edition • Over 13,500 references, more than 5,000 are papers written since 1985 Prices; each includes shipping: USA $125.00; Canada/International $130.00 (surface mail); International $170.00 (air mail). ALL ORDERS MUST BE PREPAID (Check or Credit Card) in U.S. DOLLARS International orders by check drawn on a bank in the USA or by credit card please. Order from: Montgomery Scientific Publications, P.O. Box 2704, Durham, NC 27715, U.S.A. Credit card orders accepted by fax at (919) 489-1235 (No phone orders, please.) We accept VISA,MasterCard, and Discover Card.
    [Show full text]